Search

Displaying results 1121 - 1130 of 3483 in total
  1. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  2. Drug

    Gremubamab

    go.drugbank.com/drugs/DB15014
    Investigational

    Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

  3. Drug

    Ponezumab

    go.drugbank.com/drugs/DB15135
    Investigational

    Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).

    Synonyms: PF-04360365
  4. Drug

    OP-145

    go.drugbank.com/drugs/DB05672
    Experimental

    OP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.

    Synonyms: -GLUTAMYL-L-ARGINYL-L-ISOLEUCYL-L-LYSYL-L-ARGINYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-VALYL-L-ARGINYL-L-PRO, L-ARGININE, L-ISOLEUCYLGLYCYL-L-LYSYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LYSYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-.ALPHA.
  5. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of ...

    Products: DECI SPAL-P 50
  6. Drug

    Nimacimab

    go.drugbank.com/drugs/DB15115
    Investigational

    Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).

  7. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  9. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...

  10. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: REKET - KETOCONAZOL TABLETAS X 200 MG, FUNGORAL 20 MG/ML SAMPUAN, 100 ML